(CCTA) Coronary computed tomography angiography is a diagnostic imaging procedure to visualize the coronary arteries. CCTA is a non-invasive angiogram that allows the assessment of narrowed and clogged arteries that can cause heart attack and stroke.
Coronary CTA is a non-invasive alternative to traditional angiography that offers detailed images of heart function, resulting in faster, more accurate diagnosis. It helps stratify cardiac risk in patients with low to intermediate likelihood of coronary artery disease. For some patients with chest pain, coronary CTA can rule out the need for cardiac catheterization.
Coronary imaging requires a very fast CT scan, because the coronary arteries and other cardiac structures move rapidly during the cardiac cycle. The current 'state of the art' 64 slice multi-detector row CT systems rotate around the patient in less than 500 ms. The data must be acquired monitored by an electrocardiogram, which allows the computer to reconstruct retrospectively slices at different small segments of the cardiac cycle. This cardiac synchronization reduces motion artifacts in the coronary arteries and provides movies of the beating heart and valve motion.
See also Coronary Angiogram, Calcium Score, Cardiac Phase, Cine Mode and Defibrillator.

Another term for detector, by analogy to broadcast radio receivers. Other terms used for devices of this type include modulators, phase sensitive detector and mixers.

The flare phenomenon is an increased activity uptake, seen in scintigraphic procedures in the early phases of therapy or due to healing processes.

(FNH) The focal nodular hyperplasia is a hypervascular, benign focal liver lesion. Various liver imaging techniques are common to differentiate FNH from a malign lesion, such as contrast enhanced ultrasound, MRI or a CT multi phase study.

(FDA) An agency of the US federal government established by Congress in 1912 and presently part of the US Department of Health and Human Services. The FDA gives classifications of medical devices according to potential risks and controls the safety of marketed drugs.
For more details please visit the FDA's 'Our Mission and Mandate'.

See also Class I II III Devices and Phase 1 2 3 4 Drug Trials.